Pivotal phase III trial of two dose levels of DAB(389)IL-2 (ONTAK (TM)) for the treatment of cutaneous T-cell lymphoma (CTCL)

Published

Journal Article

Full Text

Duke Authors

Cited Authors

  • Olsen, EA; Duvic, M; Martin, A

Published Date

  • April 1, 1998

Published In

Volume / Issue

  • 110 / 4

Start / End Page

  • 678 - 678

Published By

Pages

  • 1

International Standard Serial Number (ISSN)

  • 0022-202X

Language

  • English